<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570385</url>
  </required_header>
  <id_info>
    <org_study_id>35RC17_8828_DTI et NOI</org_study_id>
    <nct_id>NCT03570385</nct_id>
  </id_info>
  <brief_title>Can Diffusion Tensor Imaging (DTI) of the Optic Ways Contributes to Predict the 6 Months Prognosis of Optic Neuritis (ON)?</brief_title>
  <acronym>DTI et NOI</acronym>
  <official_title>Can Diffusion Tensor Imaging (DTI) of the Optic Ways Contributes to Predict the 6 Months Prognosis of Optic Neuritis (ON)?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can diffusion tensor imaging (DTI) of the optic ways contributes to predict the 6 months
      prognosis of Optic Neuritis (ON)?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">April 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Interventional pilot study with minimal risks and constraints, descriptive, prospective, monocentric</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study of DTI markers in the assessment of the visual prognosis at 6 months of an inflammatory NO based on RNFL thickness (&lt; ou &gt; 75 µm)</measure>
    <time_frame>Month 6</time_frame>
    <description>MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of DTI markers in the assessment of the visual prognosis at 6 months of an inflammatory NO based on visual acuity and/or sensible damage to the field of vision</measure>
    <time_frame>Month 6</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the structural anomalies detected in DTI to the standard morphological MRI (Coronal T2 Fat-Sat MRI and T1 Gadolinium) for ON</measure>
    <time_frame>Month 6</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>Patient with Optic Neuritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)</description>
    <arm_group_label>Patient with Optic Neuritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 55 years old

          -  Clinically suspected optic neuritis defined as a sudden decrease of the visual acuity
             and/or a damage to the field of vision and/or a defect of the colour vision and/or
             retro-orbital pain with a relative afferent pupillary defect (except if the optic
             neuropathy is bilateral or symmetrical), in the absence of a severe retinal macular
             pathology, and in the absence of a toxic or iatrogenic intake (ethambutol, vfend)

          -  Clinical optic neuritis duration &lt; 15 days

          -  First episode of an inflammatory ON

          -  No corticosteroids in the month before

          -  Indication to a corticosteroid therapy at high dose to cure the felt symptomatology

          -  Retinal nerve fibre layer (RNFL) thickness upper 75 µm at initial stage

          -  Isolated ON, multiple sclerosis or NMO (Neuro Myelitis Optica) - SD (Spectrum
             Disorder) context

          -  Having signed informed consent for participating in the study

        Exclusion Criteria:

          -  Contra-indication to MRI

               -  Cardiac pacemaker or defibrillator implant

               -  Neurosurgical clips

               -  Cochlear implants

               -  Intra-orbital or encephalic foreign bodies

               -  Stents implanted since less than 4 weeks and osteosynthesis equipment implanted
                  since less than 6 weeks

               -  Claustrophobia

          -  Persons subject to major legal protection (safeguarding justice, guardianship,
             trusteeship), persons deprived of liberty

          -  Eye examination suggests a pre-existing eye abnormality that could affect the visual
             function (amblyopia, strong myopia…)

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Christophe Ferré, MD-PhD</last_name>
    <phone>02.99.28.43.09</phone>
    <email>jean-christophe.ferre@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Ferré, MD-PhD</last_name>
      <phone>02.99.28.43.09</phone>
      <email>jean-christophe.ferre@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Laurent</last_name>
      <email>charlotte.laurent@chu-rennes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

